The M-gager® platform technology
The M-gager® platform is our proprietary technology that develops highly specific and effective peptide-MHC (pMHC)-targeting T cell engagers.
Based on a unique phage display library with a repertoire of billions of antibodies already binding to the pMHC of interest, the MHC-targeting T cell engager (M-gager®) format result in effective and selective recruitment of T cells and generates a specific cytotoxic T cell response against the cancer cell. M-gager® molecules are expected to be highly effective immunotherapies for challenging yet very attractive targets such as neoantigens and cancer testis antigens (CTA), providing minimal off-tumor activity.
M-gager® molecules have excellent drug properties and are well-producible in standard mammalian cell-based manufacturing.